From molecules to medicines.
Explore our pipeline

Explore the groundbreaking therapies we’re developing to give patients better treatment options

Our pipeline
Partner up?
Get in contact

We are dedicated to developing a robust and sustainable pipeline of product candidates with the potential to revolutionize patient care and improve health outcomes.

With this in mind, we’re building a broad internal pipeline of product candidates focused on the treatment of endocrine and metabolic diseases.

Discovery
Lead optimization
IND-enabling studies
Phase 1
Phase 2
Development rights
Peripheral Pain
Target: AT2R
Approach: Antagonist
Peripheral Pain
Target: AT2R
Approach: Antagonist
Phase 1

700

mil.

By 2050, over 700 million people worldwide are estimated to suffer from neuropathic pain, highlighting the urgent need for innovative treatments and effective management strategies to improve quality of life.

7-10

%

Neuropathic pain affects an estimated 7-10% of the global population, highlighting its widespread impact and the need for effective treatment solutions.

Phase 1

700

mil.

By 2050, over 700 million people worldwide are estimated to suffer from neuropathic pain, highlighting the urgent need for innovative treatments and effective management strategies to improve quality of life.

7-10

%

Neuropathic pain affects an estimated 7-10% of the global population, highlighting its widespread impact and the need for effective treatment solutions.

Confo Therapeutics is developing CFTX-1554, a non-opioid treatment for neuropathic pain. It targets the angiotensin II type 2 receptor (AT2R), addressing prior challenges of off-target toxicity in pain management.

  • Id est pulvinar dolor viverra dolor, curabitur.
  • Etiam dignissim in platea eros tellus malesuada pharetra.
More about peripheral pain
Obesity
Target: GPR75
Approach: Antagonist
Obesity
Target: GPR75
Approach: Antagonist
Lead optimization
Lead optimization
Hyperinsulinemia
Target: SSTR5
Approach: Agonist
Hyperinsulinemia
Target: SSTR5
Approach: Agonist
Lead optimization
Lead optimization
Peripheral Pain
Target: SSTR4
Approach: Agonist
Peripheral Pain
Target: SSTR4
Approach: Agonist
Lead optimization
Lead optimization
Immune-Mediated & Fibrotic Diseases
Target: MC1R
Approach: Agonist
Immune-Mediated & Fibrotic Diseases
Target: MC1R
Approach: Agonist
Lead optimization
Lead optimization
Hypoparathyroidism
Target: PTHR1
Approach: Agonist
Hypoparathyroidism
Target: PTHR1
Approach: Agonist
Discovery
Discovery
Additional Programs
Target: Multiple
Approach: MultiGen™ Platform
Additional Programs
Target: Multiple
Approach: MultiGen™ Platform
Discovery
Discovery

What makes our pipeline special?

We have a unique way to tackle validated biology

Central to the development of impactful medicines is a foundation in solid, validated biology. We are focused on discovering and developing product candidates with clear biological mechanisms to address critical unmet medical needs of patients. Our proprietary technology enables us to uniquely tackle validated biology in a way that has never been done before.

 

Our technology
Paolo ai
Paolo ai
“Our pipeline demonstrates our pursuit of therapeutic breakthroughs. Each product candidate represents hope for patients” Paolo Vicini | Chief Development Officer
Wassim ai
Wassim ai
"It’s extremely rewarding to know that our work has the potential to generate novel, groundbreaking therapies, and make a difference to patients’ lives” Wassim Ouhammou Taouni | Junior Research Associate
Rob scot hall way ai for launch
Rob ai 2
“Confo is at a pivotal stage in its growth, boasting an exciting pipeline of therapeutics targeting significant unmet needs in metabolic and endocrine diseases” Rob Scott | Independent Board Director
Joan ai final for launch
Joan ai final for launch
"We leverage our cutting-edge platform technology to accelerate the discovery and development of novel treatments in partnership with leading pharmaceutical companies.” Joan Vermeiren | Head of Development Project Management

Work with us to revolutionize GPCR-directed medicines

Whether you are looking to understand our science, partner, or build your career with us, Confo offers unique opportunities for you to help bring novel medicines to patients.

Partner with us

Explore partnership opportunities

Invest in us

Explore our investor consortium

Work with us

Join our team and shape the future